InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Rapport Therapeutics, Inc.

RAPP Clue Score35
United States Fiscal year ends December CIK 0002012593
$30.65 +2.68% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $30.65 +14.62% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 7 Jun 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−36.2Net income−34.8EPS, diluted−23.10Fiscal year 2024Operating income−83.1Net income−78.3EPS, diluted−3.78Fiscal year 2025Operating income−125.1Net income−111.5EPS, diluted−2.86
FY2023FY2024FY2025
Operating income −36.2 −83.1 −125.1
Net income −34.8 −78.3 −111.5
Growth
EPS, diluted −23.10 −3.78 −2.86

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−27.2Capital expenditure−1.6Free cash flow−28.8Fiscal year 2024Operating cash flow−64.8Capital expenditure−2.4Free cash flow−67.2Fiscal year 2025Operating cash flow−87.5Capital expenditure−0.6Free cash flow−88.1
FY2023FY2024FY2025
Operating cash flow −27.2 −64.8 −87.5
Capital expenditure −1.6 −2.4 −0.6
Free cash flow −28.8 −67.2 −88.1
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash70.2Shareholders’ equity−25.6Fiscal year 2024Cash56.8Shareholders’ equity305.4Fiscal year 2025Cash52.6Shareholders’ equity484.7
FY2023FY2024FY2025
Cash 70.2 56.8 52.6
Shareholders’ equity −25.6 305.4 484.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −25.6% −23.0%
−22.4% −24.9% −21.8%
Balance and payout
9.3% 3.0% 5.4%